Table 7.
Comparison of biomarkers among the three disease progression phases
| Viral phase (1) N = 87 |
Early inflammation (2) N = 53 |
Late inflammation (3) N = 40 |
p-value | p-value 1 vs 2 | p-value 1 vs 3 | p-value 2 vs 3 | |
|---|---|---|---|---|---|---|---|
| Neutrophils/mm3 | 5100 [3350; 6950] | 6000 [4400; 8700] | 6050 [4100; 8225] | 0.069 | 0.119 | 0.119 | 0.874 |
| IL-8 (pg/mL) | 52.01 [34.96; 68.72] | 55.52 [45.64; 91.01] | 77.32 [50.36; 106.06] | 0.002 | 0.048 | 0.002 | 0.108 |
| G-CSF (pg/mL) | 139.08 [120.98; 160.64] | 147.85 [129.84; 162.19] | 148.79 [132.43; 157.64] | 0.478 | 0.488 | 0.488 | 0.964 |
| MPO-DNA | 0.75 [0.62; 0.94] | 0.87 [0.63; 1.03] | 0.87 [0.72; 1.03] | 0.092 | 0.211 | 0.112 | 0.833 |
| NE-DNA | 1.05 [0.88; 1.25] | 1.03 [0.86; 1.25] | 0.97 [0.88; 1.27] | 0.909 | 0.868 | 0.868 | 0.868 |
| cfDNA (ng/mL) | 6.40 [3.61; 13.99] | 7.87 [5.34; 14.65] | 10.53 [5.56; 17.30] | 0.041 | 0.200 | 0.043 | 0.200 |
| CitH3 (ng/mL) | 23.64 [12.73; 35.10] | 35.89 [21.92; 61.36] | 54.54 [28.72; 91.81] | < 0.001 | 0.001 | < 0.001 | 0.043 |
Median comparison was performed using Wilcoxon signed-rank test